Combined use of mirabegron and solifenacin: new standards for successful treatment of overactive bladder

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Overactive bladder (OAB) is a common lower urinary tract disorder characterized by urgency, increased frequency, and, in some cases, urinary incontinence. Although antimuscarinic drugs (M-anticholinergics) or β3-adrenergic agonists as monotherapy provides relief to some patients, moderate treatment efficiency and tolerability often require drug switching (in case of side effects) or combination therapy (due to insufficient efficiency). The aim of this review was to analyze the combined use of mirabegron (β3-adrenergic agonist) and solifenacin (M-anticholinergic or muscarinic receptor antagonist), focusing on clinical trials, safety issues, and practical aspects. The combination therapy showed superior efficacy compared to monotherapy and an acceptable safety profile, making it a viable treatment strategy for patients with OAB who do not achieve optimal outcomes with a monotherapy.

Texto integral

Acesso é fechado

Sobre autores

Gevorg Kasyan

GBOU VO “Russian University of Medicine”; Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin of the Moscow City Health Department

Email: Khodyreva60@mail.ru

Ph.D., MD, Department of Urology

127006, Moscow, Dolgorukovskaya, 4; 125284, Moscow, 2nd Botkinsky proezd, 5, bldg. 20

Lyubov Khodyreva

GBU "Research Institute for Healthcare Organization and Medical Management" of the Moscow City Health Department

Autor responsável pela correspondência
Email: Khodyreva60@mail.ru

Ph.D., MD

Rússia, 115080, Moscow, Sharikopodshipnikovskaya st., 9

Bibliografia

  1. Kasyan G.R. Mirabegron – a new drug for the treatment of overactive bladder. Urologiia. 2015;4:121–124. Russian (Касян Г.Р. Мирабегрон – новый препарат для лечения гиперактивного мочевого пузыря. Урология. 2015;4:121–124).
  2. Gadzhieva Z.K., Atamanova E.A. Mirabegron in combination therapy of lower urinary tract symptoms in men. Innovatsionnaya farmakoterapiya. 2024;3(21):55–58. Russian (Гаджиева З.К., Атаманова Е.А. Мирабегрон в комбинированной терапии симптомов нижних мочевыводящих путей у мужчин. Инновационная фармакотерапия. 2024;3(21):55–58).
  3. Ivakhnenko O.I., Derkach E.V., Krysanova V.S., Ermolaeva A.D., Kokush- kin K.A. Mirabegron: pharmacoeconomic aspects of using the drug to treat overactive bladder. Kachestvennaya klinicheskaya praktika. 2022;1:30–40. Russian (Ивахненко О.И., Деркач Е.В., Крысанова В.С., Ермо- лаева А.Д., Кокушкин К.А. Мирабегрон: фармакоэкономические аспекты применения препарата для лечения синдрома гиперактивного мочевого пузыря. Качественная клиническая практика. 2022;1: 30–40).
  4. Dyakov I.N., Kasyan G.R. Pharmacoeconomic feasibility of using mirabegron in patients with overactive bladder. Kachestvennaya klinicheskaya praktika. 2021;1:35–45. Russian (Дьяков И.Н., Касян Г.Р. Фармакоэкономическая целесообразность применения препарата мирабегрон у больных с гиперактивным мочевым пузырем. Качественная клиническая практика. 2021;1:35–45).
  5. Drake M.J., Chapple C., Esen A.A., Athanasiou S., Cambronero J., Mitcheson D., Herschorn S., Saleem T., Huang M., Siddiqui E., Stölzel M., Herholdt C., MacDiarmid S.; BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8. PMID: 26965560.
  6. Herschorn S., Chapple C.R., Abrams P., Arlandis S., Mitcheson D., Lee K.S., Ridder A., Stoelzel M., Paireddy A., van Maanen R., Robinson D. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562-575. doi: 10.1111/bju.13882. Epub 2017 Jun 8. PMID: 28418102.
  7. Gratzke C., van Maanen R., Chapple C., Abrams P., Herschorn S., Robinson D., Ridder A., Stoelzel M., Paireddy A., Yoon S.J., Al-Shukri S., Rechberger T., Mueller E.R. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1. PMID: 29866467.
  8. Kasyan G.R., Sukhikh S.O., Pushkar D.Yu. The place of mirabegron in clinical practice. Urologiia. 2017;6:144–148. Russian (Касян Г.Р., Сухих С.О., Пушкарь Д.Ю. Место мирабегрона в клинической практике. Урология. 2017;6:144–148).
  9. Sartori L.G.F., Nunes B.M., Farah D., Oliveira L.M., Novoa C.C.T., Sartori M.G.F., Fonseca M.C.M. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis. Rev Bras Ginecol Obstet. 2023;45(6):337-346. doi: 10.1055/s-0043-1770093. Epub 2023 Jul 21. PMID: 37494577; PMCID: PMC10371066.
  10. Herschorn S., Tarcan T., Jiang Y.H., Chung E., Abdul Hadi F., Steup A., Sumarsono B. Safety and efficacy of an α1 -blocker plus mirabegron compared with an α1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis. Neurourol Urodyn. 2024;43(3):604-619. doi: 10.1002/nau.25399. Epub 2024 Jan 30. PMID: 38291827
  11. Chapple C.R., Kaplan S.A., Mitcheson D., Blauwet M.B., Huang M., Siddiqui E., Khullar V. Int J Urol. 2014;21(10):960–67. doi: 10.1111/iju.12568. Epub 2014 Aug 4.
  12. Kato D., Uno S., Van Schyndle J., Fan A., Kimura T. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. Int J Urol. 2017;24(10):757–764. doi: 10.1111/iju.13422. Epub 2017 Aug 22. PMID: 28833621.
  13. Kato D., Tabuchi H., Uno S. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study. Low Urin Tract Symptoms. 2019;11(2):O152-O161. doi: 10.1111/luts.12237. Epub 2018 Aug 5. PMID: 30079630; PMCID: PMC7379686.
  14. Gadzhieva Z.K., Atamanova E.A. Rationale for the Efficiency and Safety of Using a Beta3-Adrenergic Agent in the Drug Treatment of Overactive Bladder. Urologiia. 2019;4:116–121. Russian (Гаджиева З.К., Атамано- ва Е.А. Обоснование эффективности и безопасности применения бета3-адреномиметика в медикаментозном лечении гиперактивного мочевого пузыря. Урология. 2019;4:116–121).
  15. Apolikhina I.A., Teterina T.A., Atamanova E.A. Differentiated Approach to the Treatment of Overactive Bladder in Elderly and Senile Women. Akusherstvo i ginekologiya. 2020;9:234–240. Russian (Аполихина И.А., Тетерина Т.А., Атаманова Е.А. Дифференцированный подход к терапии гиперактивного мочевого пузыря у женщин пожилого и старческого возраста. Акушерство и гинекология. 2020;9:234–240).
  16. Gadzhieva Z.K., Kazilov Yu.B. New Possibilities for the Treatment of Combined Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia – Prerequisites and Advantages. Urologiia. 2017;1:95–102. Russian (Гаджиева З.К., Казилов Ю.Б. Новые возможности лечения комбинированных симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы – предпосылки и преимущества. Урология. 2017;1:95–102).
  17. Romikh V.V., Borisenko L.Yu., Zakharchenko A.V. Mirabegron. Will there be a revolution in pharmacotherapy of overactive bladder? Urologiia. 2015;5:110–117. Russian (Ромих В.В., Борисенко Л.Ю., Захарченко А.В. Мирабегрон. Состоится ли революция в фармакотерапии гиперактивного мочевого пузыря? Урология. 2015;5:110–117).
  18. Yamaguchi O., Kakizaki H., Homma Y., Igawa Y., Takeda M., Nishizawa O., Gotoh M., Yoshida M., Yokoyama O., Seki N., Okitsu A., Hamada T., Kobayashi A., Kuroishi K. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). Int J Urol. 2019;26(3):342-352. doi: 10.1111/iju.13868. Epub 2018 Dec 13. PMID: 30548692; PMCID: PMC7379522.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2025